# US 2015/0105338 A1 · Therapeutic compositions comprising phenolic acids for treating conditions related to inappropriate platelet aggregation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105338 A1
- Document ID: US20150105338A1
- Status: Published application
- Kind: A1
- Application number: 14/333,787
- Filed: 2014-07-17
- Published: 2015-04-16
- Earliest claimed: 2008-10-31
- Assignees: Provexis Natural Products Limited
- Applicants: Provexis Natural Products Limited
- Inventors: Niamh O'Kennedy
- Web page: https://patentgrep.com/patent/US20150105338A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond (preferably a double bond) and is substituted with one or more H or OH, for use as a medicament for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation. The compositions of the invention may be used to maintain heart health by reducing platelet aggregation; benefit the circulation; and/or normalize or otherwise benefit blood flow.

## Claims

### Claim 1

A composition comprising a therapeutically effective amount of a compound of general formula (I):
wherein R1, R2 and R3 are independently selected from H, OH and OMe; and
wherein X is C1 or C2 and wherein for C2 each carbon is linked by a single or multiple bond and is substituted with one or more H or OH.

### Claim 2 (depends on 1)

The composition according to claim 1 wherein the compound is cinnamic acid or a derivative thereof.

### Claim 3 (depends on 2)

The composition according to claim 2 wherein the compound is a derivative of cinnamic acid selected from the group consisting of: p-Coumaric acid, Caffeic acid, Ferulic acid and Sinapic acid.

### Claim 4 (depends on 1)

The composition according to claim 1 wherein the compound is benzoic acid or a derivative thereof.

### Claim 5 (depends on 4)

The composition according to claim 4 wherein the compound is a derivative of benzoic acid selected from the group consisting of: p-Hydroxybenzoic acid, Protocatechuic acid, Gallic Acid, Vanillic acid and syringic acid.

### Claim 6 (depends on 1)

The composition according to claim 1 wherein the compound is conjugated with a sugar.

### Claim 7 (depends on 6)

The composition according to claim 6 wherein the sugar is 1-5 hexose or pentose sugar residues.

### Claim 8 (depends on 6)

The composition according to claim 6 wherein the compound is selected from the group consisting of: Caffeic acid 3-O-glycoside, Caffeic acid 4-O-glycoside, Ferulic acid 4-O-glycoside, and p-Coumaric acid 4-O-glycoside.

### Claim 9 (depends on 1)

The composition according to claim 1 wherein the compound is conjugated with another molecule by an ester bond.

### Claim 10 (depends on 9)

The composition according to claim 9 wherein the compound is selected from the group consisting of Caffeoylquinic acids, 3-O-Caffeoylquinic acid, 4-O-Caffeoylquinic acid, 5-O-Caffeoylquinic acid, Feruloylquinic acids, p-Coumaroylquinic acids, Caffeoyltartaric acids, Feruloyltartaric acids, p-Coumaroyltartaric acids and dimers of quinic acid derivatives.

### Claim 11 (depends on 1)

The composition according to claim 1 further comprising a flavonoid with activity for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation.

### Claim 12 (depends on 1)

The composition according to claim 1 further comprising a nucleoside or nucleotide with activity for treating or preventing the development of medical conditions characterised by inappropriate platelet aggregation.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A nutritional product comprising a therapeutically effective amount of the composition as defined by claim 1.

### Claim 15 (depends on 1)

A pharmaceutical product comprising a therapeutically effective amount of the composition as defined by claim 1.

### Claim 16 (depends on 1)

A method of treating or reducing the likelihood of the development of medical condition in a subject characterised by inappropriate platelet aggregation, comprising:
providing a composition as defined by claim 1; and
administering a therapeutically effective amount of the composition to the subject to treat or prevent the development of the medical condition.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the treatment or prevention of the medical condition characterised by inappropriate platelet aggregation is for a purpose selected from the group consisting of: maintaining heart health by reducing platelet aggregation; benefiting the circulation; and normalizing or otherwise benefiting blood flow.
